ClinicalTrials.gg
Not yet recruitingNCT07047755Updated Jul 2, 2025

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

A Phase 2 interventional study of Trastuzumab Rezetecan and Pertuzumab in Breast Cancer, sponsored by Henan Cancer Hospital. Not yet recruiting. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Henan Cancer Hospital · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing trastuzumab rezetecan in Breast Neoplasms — 46 open to participants now, 52 under way, 10 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
45th of 53
48 · median 111
Started
2025
with 14 others
Phase 2
34 of 53
34 open now
Primary completion
2026-07
later than 10 of 51 live
Registered
23rd of 53
by date
Lead sponsor
6 of 53
Henan Cancer Hospital

Among the 53 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 45th largest by planned enrollment, is one of 15 that started in 2025, is one of 34 in phase 2, reaches primary completion later than 10 of the 51 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

46 of the 53 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

41 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open-label, phase II study evaluating the efficacy and safety of Trastuzumab Rezetecan in combination with pertuzumab in early or locally advanced HER2-positive breast cancer.

Read the detailed description

Patients with early-stage or locally advanced HER2-positive breast cancer were planned to be enrolled and subjected to neoadjuvant therapy with the regimen of Trastuzumab Rezetecan combined with Pertuzumab. The primary objective was to evaluate the efficacy and safety of Trastuzumab Rezetecan plus Pertuzumab as neoadjuvant treatment for early-stage or locally advanced HER2-positive breast cancer. Subjects will continue medication until surgery is completed, or until disease progression, intolerable toxicity, withdrawal of informed consent, or when the investigator determines that medication must be terminated.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 18-70 years;
  2. Histopathologically confirmed positive breast cancer;
  3. Patients were diagnosed with stage II-III breast cancer;
  4. At least one measurable target lesion according to V1.1;
  5. performance status score of 0 to 1;
  6. ≥12 weeks;
  7. Adequate bone marrow reserve and organ system function reserve;
  8. Participants should be able and willing to comply with the study protocol requirement;

Exclusion criteria

Exclusion Criteria:

  1. Breast cancer not confirmed;
  2. Known inherited or acquired bleeding and thrombotic tendencies;
  3. Known allergy or to the study drug and its ;
  4. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
  5. Concurrent receipt of any other form of anti-cancer therapy;
  6. History of a second primary , except for adequately treated skin cancer;
  7. Participation in other drug clinical trials within 4 weeks before enrollment;
  8. Major surgical procedures unrelated to breast cancer within 4 weeks prior to the first drug administration, or not fully recovered from such procedures;
  9. Presence of any active disease or history of autoimmune disease with potential for recurrence;
  10. Uncontrolled or significant cardiovascular and cerebrovascular diseases;
  11. Subjects with known or suspected interstitial pneumonia;
  12. Presence of active , , liver cirrhosis;
  13. Pregnant or lactating female patients;
  14. History of definite neurological or mental disorders, or any other conditions that the investigator believes make the patient unsuitable for participating in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Trastuzumab Rezetecan; Pertuzumab

    Drug: Trastuzumab Rezetecan · Drug: Pertuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. pCR rate

    Total pathological complete response (tpCR: ypT0-is,ypN0)

    Time frame: At the time of surgery

Secondary outcomes

  1. iDFS

    Invasive disease-free survival

    Time frame: Up to approximately 5 years

  2. EFS

    Event-free survival

    Time frame: Up to approximately 5 years

  3. ORR

    Objective Response Rate

    Time frame: Up to approximately 24 weeks after the first administration

  4. AEs

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to CTCAE 5.0

    Time frame: From the first dose until 30 days after last dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2026, 12 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 12 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 2, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Jul 1, 2026
CompletionEst.
Feb 28, 2031
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07047755
Responsible party
Zhenzhen Liu (Professor, Henan Cancer Hospital) — Principal investigator
First posted
Jul 2, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Feb 28, 2031 (estimated)
Last update
Jul 2, 2025

Study contacts

Zhenzhen Liu
Contact
liuzhenzhen73@126.com
+86-13603862755

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion